On March 4, 2025 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, reported that the U.S. Patent and Trademark Office has issued Natera a new patent related to testing of single nucleotide variants in circulating-tumor DNA (ctDNA) (Press release, Natera, MAR 4, 2025, View Source [SID1234650892]). This builds on Natera’s extensive intellectual property estate, including a strong portfolio of molecular residual disease testing (MRD) patents for whole exome and whole genome sequencing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
U.S. patent No. 12,203,142 relates to certain methods of preparation useful for tumor-informed ctDNA monitoring using whole exome or whole genome sequencing. The patent describes various modes of target enrichment in the plasma, including both multiplex polymerase chain reaction PCR and capture by hybridization.
Natera has more than 110 patents relating to cell-free DNA analysis for oncology testing, including 23 patents obtained in 2024